WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
PR Newswire
SUNNYVALE, Calif., April 25, 2025
SUNNYVALE, Calif., April 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the "Meeting"). A total of 59,214,893 common shares, representing approximately 40.88% of the Company's issued and outstanding shares were represented at the meeting.
The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
Votes For Votes Withheld ----------------- ------------------ ----------------- Director # % # % ----------------- ---------- ------ --------- ------ Dr. Chris Savile 46,902,346 88.3 % 6,234,676 11.7 % ----------------- ---------- ------ --------- ------ Dr. Jim Lalonde 46,965,380 88.4 % 6,171,642 11.6 % ----------------- ---------- ------ --------- ------ Donald Archibald 44,900,287 84.5 % 8,236,735 15.5 % ----------------- ---------- ------ --------- ------ Raffi Asadorian 46,963,057 88.4 % 6,173,965 11.6 % ----------------- ---------- ------ --------- ------ Al Foreman 46,900,723 88.3 % 6,236,299 11.7 % ----------------- ---------- ------ --------- ------
In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company's management information circular dated March 26, 2025 (the "Information Circular").
Votes For ---------------------------------------------------------- ------------------ Director # % ---------------------------------------------------------- ---------- ------ Appointment of KPMG LLP as the Company's auditor for the ensuring year 51,882,364 87.6 % ---------------------------------------------------------- ---------- ------ The proposed sale of the shares of Epimeron USA, Inc., the Corporation's wholly-owned subsidiary, as more particularly described in the Information Circular 46,996,397 88.4 % ---------------------------------------------------------- ---------- ------ To authorize the Corporation's board of directors, at its sole discretion, to amend the Articles of the Corporation to change its name from "Willow Biosciences Inc." to "2482118 Alberta Ltd.", or such other name as may be approved by the Board, as more particularly described in the Information Circular. 48,853,362 82.5 % ---------------------------------------------------------- ---------- ------
For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated April 25, 2025, available on SEDAR+ at www.sedarplus.ca.
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrown$(TM)$ biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
For more information, visit www.willowbio.com or contact:
Travis Doupe
Chief Financial Officer
E: info@willowbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-announces-annual-general-and-special-meeting-voting-results-302438831.html
SOURCE Willow Biosciences Inc.
(END) Dow Jones Newswires
April 25, 2025 19:22 ET (23:22 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.